Evidence map›Paper›PMID 33638897›Full record

ArticleJournal of applied microbiology2021

N-chlorotaurine, a potent weapon against multiresistant bacteria.

C Anich, D Orth-Höller, M Lackner, M Nagl

Open access · hybridAbstract read
In one paragraph

Article in Journal of applied microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Frontiers in veterinary science · 2025
    Article
  3. Long-Term Stability and Efficacy of NCT Solutions.International journal of molecular sciences · 2024
    Article
  4. Activity ofInternational journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

C AnichInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
D Orth-HöllerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0003-2904-5192
M LacknerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0001-9073-2886
M NaglInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.ORCID https://orcid.org/0000-0002-1225-9349
Innsbruck Medical University · AT

Funding

Austrian Cystic Fibrosis self-regulating community
6 · The paper itself

Abstract

aimsN-chlorotaurine (NCT) is a body-own mild oxidizing antiseptic that can be applied topically as a well-tolerated anti-infective at many body sites. The objective of this study was to demonstrate its activity against representative nosocomial multidrug-resistant bacteria. METHODS AND

resultsThe bactericidal activity of NCT was tested in quantitative killing assays against a panel of multiresistant Gram-positive and Gram-negative clinical isolates. N-chlorotaurine (1%, 55 mmol l

conclusionThe activity of NCT against these clinical isolates is similar to that against non-resistant ATCC strains and therefore not influenced by antibiotic resistance. This can be explained by the oxidizing and chlorinating mechanism of action of NCT, which leads to an attack of multiple targets in the microorganisms. SIGNIFICANCE AND IMPACT OF THE STUDY: The bactericidal spectrum of NCT is not restricted by resistance against antibiotics. Therefore, it can be used against resistant strains, too.

Indexed as

Methicillin-Resistant Staphylococcus aureusAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative BacteriaMicrobial Sensitivity TestsTaurineAnti-Bacterial AgentsN-chlorotaurineTaurineanti-infectiveantisepticchloraminesmultiresistant bacteriaN-chlorotaurineresistance

Identifiers

PMID33638897
PMCPMC8518795
OpenAlexW3131849650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.